


Measles and rubella elimination country profile

Turkmenistan

Measles elimination status


2016 eliminated
2017 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Rubella elimination status

2016 eliminated
2017 eliminated




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Measles and rubella surveillance

National case-based surveillance for measles, rubella and CRS

Lab confirmation for diagnosis of measles, rubella and CRS



Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Demographic information, 2017

Total population	5 758 075
< 1 year old	144 375
< 5 years old	712 487

Source: World Population Prospects: The 2017 Revision, New York, United Nations

Measles and rubella immunization schedule, 2017


	Vaccine	Schedule	Year of introduction	
MCV1	MMR	12-15 months	MCV2	1988
MCV2	MMR	6 years	RCV	2007
Measles vaccination in school				No

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MMR = measles-mumps-rubella vaccine; MCV1 = first dose measles-containing vaccine;

MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Measles and rubella cases and immunization coverage, 2008–2017



Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MCV1 = first dose of measles-containing vaccine

MCV2 = second dose of measles-containing vaccine

Definition used for an outbreak

ND



Source: Measles and rubella elimination Annual Status Update report, 2017

ND = Data not available

Supplementary immunization activities

Year	Target age	Vaccine used	% Coverage
2017	2-10Y	MMR	99%

Source: Supplementary immunization activities, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)

MMR = measles-mumps-rubella vaccine

ND = Data not available



Measles and rubella elimination country profile

Turkmenistan

Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2013	128	0	0	0	0	128	0	NA
2014	129	0	0	0	0	129	0	NA
2015	377	0	0	0	0	377	0	NA
2016	193	0	0	0	0	193	0	NA
2017	126	0	0	0	0	126	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non-measles rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	2.2	100%	100%	0%	128	0%	NA	100%
2014	2.2	100%	100%	0%	129	0%	NA	100%
2015	6.3	100%	100%	0%	377	0%	NA	100%
2016	3.2	100%	100%	0%	193	0%	NA	100%
2017	2	100%	100%	NA	126	0%	NA	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected rubella cases	Confirmed rubella cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi- linked	Clinically	Total			
2013	128	0	0	0	0	128	0	NA
2014	129	0	0	0	0	129	0	NA
2015	377	0	0	0	0	377	0	NA
2016	193	0	0	0	0	193	0	NA
2017	126	0	0	0	0	126	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella surveillance and laboratory performance indicators, 2013-2017

	Discarded non-rubella rate	% 1st sub-national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	2.2	100%	100%	0%	128	0%	NA	100%
2014	2.2	100%	100%	0%	129	0%	NA	100%
2015	6.3	100%	100%	0%	377	0%	NA	100%
2016	3.2	100%	100%	0%	193	0%	NA	100%
2017	2	100%	100%	NA	126	0%	NA	100%

Source: ASU 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Turkmenistan in 2017 and confirmed that measles and rubella elimination has been sustained.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrv

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: ≥ 80%
- % origin of infection known: ≥ 80%
- Rate of viral detection: ≥ 80%

Information on CRS, 2017

No cases reported



Source: Measles and rubella elimination Annual Status Update report, 2017
CRS = congenital rubella syndrome